CFM
ADPT icon

Catalyst Funds Management’s Adaptive Biotechnologies ADPT Stock Holding History

Catalyst Funds Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-2,000
Closed -$10.2K – 319
2024
Q3 		$10.2K Buy
2,000
+1,100
+122% +$4.79K ﹤0.01% 1184
2024
Q2 		$3.26K Buy
+900
New +$2.86K ﹤0.01% 1100

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Catalyst Funds Management's ADPT Position: Q4 2024 in Review

Catalyst Funds Management sold out of Adaptive Biotechnologies (ADPT) in Q4 2024, closing a stake of 2,000 shares — an estimated $10.2K sold.

Catalyst Funds Management first reported a position in ADPT in Q2 2024 and held it in 2 quarters. The position peaked at $10.2K in Q3 2024. 207 funds tracked by Wall St. Rank hold ADPT as of Q4 2024.

  • Catalyst Funds Management reported no remaining Adaptive Biotechnologies position as of Q4 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 2,000 Adaptive Biotechnologies shares in Q4 2024, an estimated $10.2K.
  • Catalyst Funds Management first reported a position in Adaptive Biotechnologies in Q2 2024 and held it in 2 quarters.
  • Catalyst Funds Management's Adaptive Biotechnologies position peaked at $10.2K in Q3 2024.
  • 207 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2024.

Based on Catalyst Funds Management's 13F filing for Q4 2024, filed 10 Feb 2025.